A biopharmaceutical company developing novel therapeutics based on RNA interference, which is a naturally occurring biological pathway within cells for selectively silencing and regulating specific genes.


Updates from The Motley Fool

Latest updates on Alnylam Pharmaceuticals from Fool.com.


Stock Performance

ALNY vs. S&P 500 | 2 Year Performance
View Interactive ALNY Charts
Sponsored by

Key Data Points

Primary metrics and data points about Alnylam Pharmaceuticals.
Current Price: $71.56
Prev Close: $70.80
Open: $71.10
Bid: $63.00
Ask: $71.56
Day's Range: $70.22 - $71.84
52wk Range: $49.96 - $116.96
Volume: 402,051
Avg Vol 717,021
Market Cap: $6.06B
P/E (ttm): -16.70
EPS (ttm): -$4.24
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Alnylam Pharmaceuticals.
CAPS Rating 4 out of 5
 
379 Outperform
38 Underperform
CAPS All Stars
 
82 Outperform
17 Underperform

How do you think Alnylam Pharmaceuticals will perform against the market?



You pick for Alnylam Pharmaceuticals is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

John M. Maraganore, CEO

85% Approve

Based on 12 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Alnylam Pharmaceuticals.

A biopharmaceutical company developing novel therapeutics based on RNA interference, which is a naturally occurring biological pathway within cells for selectively silencing and regulating specific genes.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers